Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/Rheumatologyblue cross blue shield - louisiana IV Cosentyx Cov…
    Ask Trek AI about this page
    Currentblue cross blue shield - louisianaPolicy MA-223

    Secukinumab (Cosentyx) — intravenous (Medicare Advantage)

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy MA-223 alerts

    Get alerted when Policy MA-223 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Advantage medical policy governing coverage criteria for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis for members of the Health Plan.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicySecukinumab (Cosentyx) — intravenous (MA-223)
    Policy CodePolicy MA-223
    Change TypeNo material change
    Effective DateSep 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain prior authorization for initial and continuation intravenous Cosentyx; continuation requires documentation of benefit after ≥6 months or prior plan authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    18+minimum age for adult indications covered by IV formulation
    6 monthsrequired minimum therapy duration before continuation approval
    1.75 mg/kg q4wmaintenance dosing permitted
    All codes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    prior auth requirement
    6 mg/kgloading dose option at Week 0

    Coverage Criteria for Intravenous Secukinumab (Cosentyx)

    Initial Therapy — Psoriatic Arthritis

    Covered when ALL of the following are met

    Psoriatic arthritis initial: Patient has a diagnosis of active psoriatic arthritis; AND Patient has a negative TB test prior to treatment; AND Cosentyx is NOT used in combination with other biologic DMARDs or specified drugs (e.g., adalimumab, Enbrel, Otezla, Xeljanz/XR); AND Patient has failed treatment with one or more traditional DMARDs (e.g., methotrexate) unless contraindicated; AND Patient is 18 years of age or older; AND ONE of the following dosing regimens will be used: WITH loading dose 6 mg/kg at Week 0 then 1.75 mg/kg every 4 weeks not exceeding 300 mg per infusion OR WITHOUT loading dose 1.75 mg/kg every 4 weeks not exceeding 300 mg per infusion.age >=18; max maintenance dose 300 mg

    From policy initial criteria for psoriatic arthritis

    Continuation Therapy — Psoriatic Arthritis

    Covered when ALL of the following are met

    Psoriatic arthritis continuation: Patient has received an initial authorization for Cosentyx from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan; AND Patient has received at least 6 months of therapy with the requested drug; AND Cosentyx is NOT used in combination with other biologic DMARDs or specified drugs (e.g., adalimumab, Enbrel, Otezla, Xeljanz/XR); AND Patient has received a beneficial clinical response from baseline evidenced by at least ONE of: improvement on an objective measure (e.g., DAPSA, CPDAI, PsA DAS, serum markers), less joint pain, decreased morning stiffness or fatigue, improved function/ADLs, decreased soft tissue swelling; AND requested dose is 1.75 mg/kg every 4 weeks not exceeding the maximum maintenance dose of 300 mg per infusion.>=6 months therapy; maintenance dosing 1.75 mg/kg q4w (<=300 mg)

    Continuation criteria for psoriatic arthritis

    Initial Therapy — Ankylosing Spondylitis

    Covered when ALL of the following are met

    Ankylosing spondylitis initial: Patient has a diagnosis of active ankylosing spondylitis; AND Patient is 18 years of age or older; AND Patient has a negative TB test prior to treatment; AND Cosentyx is NOT used in combination with other biologic DMARDs or specified drugs (e.g., adalimumab, Enbrel, Otezla, Xeljanz/XR); AND Patient has failed treatment with NSAIDs or has documented contraindication to NSAIDs; AND ONE of the following dosing regimens will be used: WITH loading dose 6 mg/kg at Week 0 then 1.75 mg/kg every 4 weeks not exceeding 300 mg per infusion OR WITHOUT loading dose 1.75 mg/kg every 4 weeks not exceeding 300 mg per infusion.age >=18; max maintenance dose 300 mg

    Initial criteria for ankylosing spondylitis

    Continuation Therapy — Ankylosing Spondylitis

    Covered when ALL of the following are met

    Ankylosing spondylitis continuation: Patient has received an initial authorization for Cosentyx from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan; AND Patient has received at least 6 months of therapy with the requested drug; AND Cosentyx is NOT used in combination with other biologic DMARDs or specified drugs (e.g., adalimumab, Enbrel, Otezla, Xeljanz/XR); AND Patient has received a beneficial clinical response from baseline evidenced by at least ONE of: improvement on an objective measure (e.g., ASDAS, ASQoL, HAQS, serum markers), decreased pain or stiffness, improvement in function/ADLs; AND requested dose is 1.75 mg/kg every 4 weeks not exceeding the maximum maintenance dose of 300 mg per infusion.>=6 months therapy; maintenance dosing 1.75 mg/kg q4w (<=300 mg)

    Continuation criteria for ankylosing spondylitis

    Initial Therapy — Non-radiographic Axial Spondyloarthritis

    Covered when ALL of the following are met

    Non-radiographic axial spondyloarthritis initial: Patient has active non-radiographic axial spondyloarthritis confirmed by sacroiliitis on MRI; AND Patient has failed at least TWO months of continuous therapy with at least TWO different oral NSAIDs at prescription strength unless contraindicated; AND Patient is 18 years of age or older; AND Cosentyx is NOT used in combination with other biologic DMARDs or specified drugs (e.g., adalimumab, Enbrel, Otezla, Xeljanz/XR); AND Patient has a negative TB test prior to treatment; AND ONE of the following dosing regimens will be used: WITH loading dose 6 mg/kg at Week 0 then 1.75 mg/kg every 4 weeks not exceeding 300 mg per infusion OR WITHOUT loading dose 1.75 mg/kg every 4 weeks not exceeding 300 mg per infusion.age >=18; failed >=2 months on >=2 NSAIDs; max maintenance dose 300 mg

    Initial criteria for non-radiographic axial spondyloarthritis

    Continuation Therapy — Non-radiographic Axial Spondyloarthritis

    Covered when ALL of the following are met

    Non-radiographic axial spondyloarthritis continuation: Patient has received an initial authorization for Cosentyx from the plan OR has provided documentation of authorization for an active course of treatment from a previous health plan; AND Patient has received at least 6 months of therapy with the requested drug; AND Cosentyx is NOT used in combination with other biologic DMARDs or specified drugs (e.g., adalimumab, Enbrel, Otezla, Xeljanz/XR); AND Patient has received a beneficial clinical response from baseline evidenced by at least ONE of: improvement on an objective measure (e.g., ASDAS, ASQoL, BASDAI, BASFI, serum markers), decreased pain or stiffness, improvement in function/ADLs; AND requested dose is 1.75 mg/kg every 4 weeks not exceeding the maximum maintenance dose of 300 mg per infusion.>=6 months therapy; maintenance dosing 1.75 mg/kg q4w (<=300 mg)

    Continuation criteria for non-radiographic axial spondyloarthritis

    Coverage criteria for IV secukinumab (adult indications)

    Covered when ALL of the following are met for FDA-indicated adult uses of the intravenous formulation:

    Indication: Use is for an FDA-approved adult indication allowed for IV formulation (psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis)

    IV formulation may only be administered in adults for these indications

    Prior therapy: Patients have had appropriate first-line therapy when applicable (e.g., NSAIDs for axial spondyloarthritis; DMARDs such as methotrexate for psoriatic arthritis) before biologic use

    Step therapy expectations described in background and disease sections

    Authorization: A prior authorization is obtained for the requested code(s)

    All codes listed require prior authorization

    Use of secukinumab (Cosentyx) for indications other than the adult rheumatologic conditions listed in this policy (psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis) is considered investigational and is not covered by the Health Plan.

    When the specific patient selection criteria in this policy are not met, use of secukinumab (Cosentyx) is considered investigational and may be denied. Exceptions explicitly noted as not medically necessary elsewhere in the policy remain subject to those determinations.

    Use of secukinumab is considered not medically necessary when required patient selection criteria for the specific disease are not fulfilled. Examples include failure to meet step-therapy requirements (e.g., for psoriatic arthritis: failure of one or more traditional DMARDs), insufficient duration of prior therapy or inadequate documentation for continuation (e.g., less than 6 months of prior Cosentyx therapy), or lack of documented clinical benefit (for example, no objective improvement on measures such as DAPSA, ASDAS, BASDAI, or no reduction in pain, stiffness, or functional impairment).

    Investigational use determinations may trigger denials when patient-selection criteria are unmet or when the requested indication is outside those listed in this policy. Prior authorization is required for all requests; continuation approvals additionally require documentation of prior authorization or prior-plan authorization and evidence of benefit after at least 6 months of therapy. Uses explicitly designated as not medically necessary (see examples above) remain subject to those policies and are not eligible for investigational exceptions.

    Coding

    Applicable HCPCS CodesHCPCSCovered
    J3247Secukinumab injection, intravenous (as listed in policy)
    Related ICD-10 Diagnosis CodesICD-10
    All Related DiagnosesICD-10 diagnosis codes related to indications
    CPTCPT
    No CPT codes listedPolicy notes CPT codes are used generally; no specific CPT codes provided in this section

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization required for initial and continuation therapy

    Initial and continuation use of intravenous Cosentyx (secukinumab) require prior authorization. Continuation requests must include either an initial authorization from this plan or documentation of an active course authorization from a previous health plan and evidence of benefit after at least 6 months of therapy.

    • Continuation requires documentation of prior authorization from this plan OR documentation of authorization for an active course of treatment from a previous health plan.
    • Continuation requires at least 6 months of therapy and demonstration of clinical benefit per continuation criteria.
    Prior Authorization

    Prior authorization required for associated codes (e.g., J3247)

    All codes listed on this medical policy require prior authorization; for the intravenous formulation this includes HCPCS J3247 (secukinumab injection, intravenous).

    • NOTICE: All codes listed on the Medical Policy require prior authorization.

    Background

    Cosentyx (secukinumab) is a human interleukin-17A antagonist available in subcutaneous pens/syringes (75 mg, 150 mg, 300 mg) and an intravenous formulation supplied as a 125 mg vial. The intravenous formulation is intended for administration in adults and, per this policy, may only be used for the specified adult rheumatologic indications. Dosing regimens for the IV formulation include an optional loading dose of 6 mg/kg at Week 0 followed by maintenance dosing of 1.75 mg/kg every 4 weeks (maximum 300 mg per infusion), or maintenance dosing without a loading dose at the same weight-based rate and maximum.

    Definitions

    Cosentyx (IV) — key facts
    FormulationIntravenous Cosentyx supplied as 125 mg vial for IV infusion
    Intended populationAdults only — IV formulation may only be administered in adults for psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis
    Relation to other formulationsIV vial is distinct from subcutaneous pens/syringes (150 mg and 300 mg) and pediatric 75 mg syringe
    MechanismHuman interleukin-17A (IL-17A) antagonist inhibiting pro-inflammatory cytokines and chemokines
    Cosentyx (secukinumab) — formulations
    Active ingredientSecukinumab (Cosentyx)
    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicySecukinumab (Cosentyx) — intravenous (MA-223)
    Policy CodePolicy MA-223
    Change TypeNo material change
    Effective DateSep 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain prior authorization for initial and continuation intravenous Cosentyx; continuation requires documentation of benefit after ≥6 months or prior plan authorization.
    SourceLink
    On This Page
    Coverage Criteria for Intravenous Secukinumab (Cosentyx)CodingProvider Actions, Prior Authorization, and DocumentationBackgroundDefinitions
  1. Applicable HCPCS code: J3247 for secukinumab intravenous.
  2. Step Therapy

    Step therapy requirements and exceptions

    Step therapy is required before IV Cosentyx in the specified diseases: psoriatic arthritis requires failure of one or more traditional DMARDs (e.g., methotrexate) unless contraindicated; ankylosing spondylitis and non‑radiographic axial spondyloarthritis require failure of appropriate NSAID therapy as specified.

    • Psoriatic arthritis: failed treatment with one or more traditional DMARDs unless clinical evidence/history contraindicates their use.
    • Ankylosing spondylitis: failed treatment with NSAIDs or documented contraindication to NSAIDs.
    • Non‑radiographic axial spondyloarthritis: failed at least two months of continuous therapy with at least two different oral NSAIDs at prescription strength unless contraindicated.
    Step Therapy

    Require conventional therapy (DMARDs/NSAIDs) before biologic

    Conventional therapy must be tried before biologic IV Cosentyx for these indications: DMARDs (e.g., methotrexate) for psoriatic arthritis and NSAIDs for ankylosing spondylitis and non‑radiographic axial spondyloarthritis per the policy's prior‑therapy expectations.

    • Psoriatic arthritis: traditional DMARDs are typical first‑line treatments prior to biologics.
    • Axial spondyloarthritis (including non‑radiographic): oral NSAIDs are standard first‑line therapy; multiple NSAIDs may need to be tried because response varies.
    Documentation Required

    Documentation required for continuation (authorization and clinical benefit)

    For continuation authorization, provide documentation of the initial authorization or proof of a prior plan's authorization for an active course of treatment, plus objective or clinical evidence of a beneficial response after at least 6 months of therapy.

    • Evidence of benefit may include improvement on objective measures (e.g., DAPSA, CPDAI, PsA DAS, ASDAS, BASDAI), decreased pain/stiffness, improved function/ADLs, decreased morning stiffness or fatigue, or decreased soft tissue swelling.
    • Requested maintenance dose must be 1.75 mg/kg every 4 weeks not exceeding 300 mg per infusion.
    Documentation Required

    Provide prior‑plan authorization documentation for transitions

    If a member has an existing authorization from another health plan, supply documentation of that prior authorization to receive a 90‑day transition; the services must otherwise be covered under this plan.

    • Documentation of the previous plan's authorization must be provided by the member or their provider to qualify for the transition period.
    • All codes listed on the Medical Policy still require prior authorization under this plan.
    Denial Risk

    Triggers for denial — unmet selection criteria and insufficient documentation

    Denials commonly result when patient selection criteria are not met — for example, failure to document required prior therapies, insufficient duration of therapy for continuation (less than 6 months), or lack of documented clinical benefit on continuation requests.

    • Psoriatic arthritis denials: no evidence of prior DMARD failure or <6 months of therapy or no documented clinical benefit.
    • Axial spondyloarthritis denials: no evidence of prior NSAID failure or <6 months of therapy or no documented clinical benefit.
    Denial Risk

    Investigational use outside listed indications is denied

    Use of secukinumab (Cosentyx) for indications not listed in this policy or when patient selection criteria are not met is considered investigational and will be denied.

    • Investigational determinations apply when patient selection criteria are not met or for any indication other than the FDA‑approved adult indications listed (psoriatic arthritis, ankylosing spondylitis, non‑radiographic axial spondyloarthritis).
    Available subcutaneous strengths
    Pens and prefilled syringes: 150 mg and 300 mg (adults); 75 mg syringe for pediatric patients
    Available intravenous strength125 mg vial for intravenous infusion
    Therapeutic classIL-17A antagonist (interleukin blocker)
    Non-radiographic axial spondyloarthritis — definition & diagnostic notes
    DefinitionAxial spondyloarthritis that is not evident on plain radiography; diagnosis supported by MRI evidence of active sacroiliac inflammation
    Typical presentationChronic back pain often beginning before age 45, may be accompanied by synovitis, enthesitis, dactylitis, uveitis, psoriasis, or inflammatory bowel disease
    Initial pharmacologic therapyOral NSAIDs are traditional first-line therapy; multiple NSAIDs may be tried because response is variable
    When to consider biologic therapyIf response to two different NSAIDs is inadequate, consider a TNF inhibitor or interleukin blocker (e.g., Cosentyx)